At a glance

What is DSIP?

DSIP, delta sleep-inducing peptide, is a naturally occurring nine-amino acid peptide first isolated decades ago from the blood of sleeping rabbits. It is sold through wellness and "research peptide" channels for sleep and stress, though its role in the body is still not well understood. It is not an approved medicine.

What is the history of DSIP?

DSIP was discovered in the 1970s out of a long-standing question in sleep science: whether sleep is driven by a chemical that circulates in the blood. Working in Switzerland, the physiologist Marcel Monnier and colleagues ran cross-circulation experiments in rabbits, electrically stimulating a sleep-related region of the brain in one animal and passing its blood to a second, which then showed the slow, high-amplitude "delta" brain waves of deep sleep. That pointed to a sleep-promoting substance carried in the blood.

In 1977, Guido Schoenenberger, Monnier, and their co-workers isolated and synthesized¹ that substance, a nine-amino-acid peptide they named delta sleep-inducing peptide after the delta-wave sleep it was linked to. Having a synthetic version made the peptide available for wider study.

Over the following decades, researchers looked beyond sleep, exploring possible roles in stress, body temperature, pain, and antioxidant activity, but the findings never converged into a validated mechanism or an approved therapy. DSIP was later shown to occur naturally in humans as well as animals. Despite nearly fifty years of study, it remains an experimental compound rather than a medicine, sold today through wellness and "research peptide" channels.

How does it work?

DSIP has been proposed to play roles in:

• Regulating sleep
• Modulating the body's stress (HPA-axis) responses
• Acting as an antioxidant

It has no validated receptor or defined mechanism. The sleep association that gave it its name comes from early animal work that has not resolved into a clear understanding of how, or whether, it influences human sleep. This describes a proposed mechanism, separate from any demonstrated benefit.

Is it FDA-approved?

No. DSIP is not approved by the FDA and is not approved as a drug in any country; it is sold only through research and gray-market channels and is not on FDA compounding lists. As a neutral regulatory note, a related sleep compound was reviewed at a 2026 FDA compounding advisory meeting and received an unfavorable vote.

What does the research show?

The human evidence is thin and old. A small number of studies from the 1980s and 1990s examined DSIP in insomnia², chronic pain³, and withdrawal states⁴ and reported inconsistent findings; most were small and uncontrolled, and no modern, well-conducted trials have established a reproducible benefit. There is no sound human evidence that DSIP improves sleep or stress.

More for brain & sleep